Consider baseline risk of lung cancer. Scleroderma and RA in particular at increased risk => lower threshold for getting initial CT. For incidental nodule, consider rescreening at 6-12 months, then space out. #ACR2021

Brepocitinib (TYK2/JAK1i) superior to PBO in PsA at week 16, w/ improvements in refractory domains continuing over 52 weeks. There were more AEs in the brepocitinib groups vs PBO over 16 weeks. Abs 0488 #ACR21 #RheumNow @RheumNow https://t.co/umk4REJwkS https://t.co/JYZVR3jyY5

• Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor…

BE AGILE: No new safety signals in AS pts treated with BKZ ( IL-17F/IL-17Ai) and remains efficacious as a potential treatment in AS. Abs 0491 #ACR21 #RheumNow @RheumNow https://t.co/fGT8n5Hx9C https://t.co/rjPTla7JId

• Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylit…

Common sense to ⬇️#rheumatoidarthritis 6S412 G Burmester summarizes decades of RA research - avoidance strategies =healthy lifestyle. ?asked is sero+RA diff than seronegative? Maybe. other Abs likely exist @RheumNow #ACR21 #ACRBest https://t.co/RT3dHDfdWp

After elegantly laying out the sophisticated science at #ACR21, Gerd Burmester finishes with this: Without waiting, 11 things we can actually do now to reduce our chance of RA @The_IMJ Ranjeny Thomas and @lynmarch1 et al @RheumNow https://t.co/Be1Jyw9FOo

I'm wearing my badge, just in case... #RheumPix https://t.co/UvgCinq8Bn

Spinal involvement: fine, symmetric syndesmophytes (axSpA) vs bulky, asymmetric syndesmophytes (axPsA) #ACR21 https://t.co/7leGTjm4fb

@AUGarren @DavidLeverenz demonstrate significant gaps in DMARD lab safety monitoring in telehealth setting. Small improvement over time but still <50% 😱 Abstr#0146 #ACR21 @RheumNow https://t.co/FDp7ZwzfO5

Deucravacitinib (TYK2 inhibitor) for PsA tx showed biomarker changes consistent with clinical improvement ⬇️IL-23, IL-17 and IFN-1 pathways vs. pbo ⬇️MMP3 (associated with joint damage), C4M Abs#490 #ACR21 @RheumNow https://t.co/mA1aHmtE5I https://t.co/BoAPKiMW9x

• Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, …

Skin Findings in Patients of Color with Rheumatic Disease #ACR21. Don't miss lupus panniculitis. https://t.co/kM6XbFtNoW

Brepocitinib (TYK2/JAK1 inhibitor) phase 2b study for PsA treatment ⬆️ACR20, 50, 70 response vs. pbo ⬆️secondary outcomes vs. pbo ⬆️serious AE vs. pbo, ⬆️zoster ⭐️no MACE/VTE/death reported Abs#488 #ACR21 @RheumNow https://t.co/KdAHQGjTMZ https://t.co/ugk3rkxX9t

• Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor…

OK am trying to learn about VEXAS ⬇️hearing, periorbital Edelman, chondritis, VTE, pulmonary infiltrates, Sweets, Arthritis. Genetic adult auto inflammatory syndrome ⬆️Men Rx steroids, then IL6i, etc. IL1i has ⬆️skin reactions 6S410 #ACR21 #gamechanger @RheumNow #ClinicalPearl https://t.co/OYRi1yAal5

Too many great points in this presentation! Making sense of the IL-23 inhibitor failure in axSpA studies. From Dr. Atul Deodhar's presentation at #ACR21 6S403 session @RheumNow https://t.co/Iv0LCNob5J

Abst 0482 Baker and colleagues showed that in patients with Type 2 DM, metformin use is associated with significantly lower risk of developing #OA and time to joint replacement #ACR21 @RheumNow https://t.co/a00g3HMrM0

🚨 DESIRES study. DB RCT in systemic sclerosis. Significant benefit of Rituximab in Rodnan skin score and FVC! Abstr#496 #ACR21 @RheumNow #ACRBest https://t.co/Ta6Cq8XZie